© 2024 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Latest Conference Articles
PF-05280586 is Similar to Reference Rituximab in Follicular Lymphoma
Samantha DiGrande
December 1 2018
American Society of Hematology Annual Meeting and Exposition
The researchers concluded that the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of PF-05280586 and the reference were similar at the conclusion of the study at week 26.
Celltrion Weighs in on Biosimilar Uptake Challenges in the United States
Samantha DiGrande
November 19 2018
A key factor in overcoming barriers to United States market entry is sharing the positive experiences of both healthcare professionals and patients, explained HoUng Kim, Head of Strategy and Operations Division, Celltrion Healthcare during a presentation at SMi Biosimilars USA Conference in Iselin, NJ, that took place November 14-15, 2018.
Systematic Review Finds "Low Risk" of Safety Concerns or Loss of Efficacy Following Switch to a Biosimilar
Samantha DiGrande
November 17 2018
Being able to switch from a reference product to a biosimilar is important for 3 reasons, explained Hillel Cohen, PhD, executive director of scientific affairs at Sandoz, during his presentation at SMi Biosimilars USA Conference in Iselin, New Jersey, held November 14-15, 2018.
Experts Discuss BPCIA Litigation Confusion, Differences Between IPRs and PGRs
Samantha DiGrande
November 15 2018
Experts from Venable, Alkermes, and Novartis provide updates to the Biologics Price Competition and Innovation Act of 2009 (BPCIA) and explain the differences between inter partes review (IPR) and post grant review (PGR) litigation.
Can the Biosimilar Market Achieve Long-Term Sustainability?
Samantha DiGrande
November 15 2018
During the first day of the SMi Biosimilars Meeting held in Iselin, New Jersey, from November 14-15, 2018, Christina Yunis, global biosimilars market development lead at Pfizer, discussed the sustainability of and challenges seen in the biosimilars market from an industry perspective.
Positive Clinical Trial Results for 2 Proposed Pegfilgrastim Biosimilars
Kelly Davio
October 25 2018
Pegfilgrastim, a long-acting granulocyte-colony stimulating factor (G-CSF) therapy, has become a key product for the prophylaxis and treatment of febrile neutropenia, and biosimilar options have the potential to reduce the high cost of pegfilgrastim therapy. At the European Society for Medical Oncology 2018 Congress, held October 19-23, 2018, in Munich, Germany, 2 research teams presented on studies assessing proposed pegfilgrastim biosimilar products.
Biosimilar Epoetin Alfa Improves Both Hemoglobin Levels and Quality of Life
Kelly Davio
October 25 2018
Anemia is a common complication for patients who are undergoing chemotherapy, and one that has implications for patients’ quality of life, especially with respect to fatigue. During the European Society for Medical Oncology 2018 Congress, held October 19-23, 2018, in Munich, Germany, Jérôme Desrame, MD, reported on results of the CIROCO study, which assessed fatigue in patients with chemotherapy-induced anemia who were treated with biosimilar epoetin alfa.
As Reassuring Data on Anticancer Biosimilars Grow, ESMO Ups Its Biosimilar Education
Samantha DiGrande
October 24 2018
The European Society for Medical Oncology (ESMO) 2018 Congress, held October 19-23, 2018, in Munich, Germany, featured multiple presentations on biosimilars in oncology, all of which are contributing to the body of evidence that points to the safety and efficacy of these products. Despite such reassuring data for biosimilars, however, many stakeholders have noted that lack of provider education on biosimilars is holding back progress with uptake.
Lessons Learned From Denmark's Biosimilars Success
Kelly Davio
October 24 2018
Among European nations, Denmark has had some of the greatest success with leveraging biosimilars to reduce cost burdens on its healthcare system, and during the fifth DIA Biosimilars Conference, held October 22 to 23, 2018, in London, United Kingdom, stakeholders heard directly from Dorthe Bartels, MSc, on how Denmark has achieved its strong biosimilar uptake.
FDA's Leah Christl Provides an Update on the Biosimilar Action Plan
Kelly Davio
October 23 2018
While it is indeed the case that the current administration has made drug pricing and biosimilars a priority, and while the Biosimilar Action Plan was hailed as a major step forward for biosimilars in the United States, “It’s not the only plan that’s going to exist,” said the FDA's Leah Christl, PhD.